fda statement bpc-157 not approved fda.gov vs. TB-500: What Patients Should Know FDA peptide review could lead

Weersma RK, Zhernakova A, Fu J

The percentages of participants who experienced AE leading to treatment discontinuation as well as of those who experienced gastrointestinal AE with oral semaglutide 50 mg (Tables 2 and 3) were similar to those observed with subcutaneous semaglutide 2.4 mg (in STEP-1 and STEP-2 trials 67% discontinued treatment due to AE, 3444% experienced nausea, 2132% diarrhoea and 2225% vomiting) [11, 29]

Clinical studies injury type A Although theoretically possible, there are not currently any clinical studies showing concurrent disc degeneration after low energy spine trauma without any detectable damage of the vertebral bone including the endplates or intervertebral disc

O'Brien NC, Charlton B, Cowden WB, Willenborg DO